[1]
|
中国老年2型糖尿病防治临床指南编写组. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志, 2022, 30: 2-51. doi: 10.3969/j.issn.1006-6187.2022.01.002 |
[2]
|
Li Y, Teng D, Shi XG, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369: m997. |
[3]
|
Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group[J]. Diabetes Care, 1997, 20: 1664-1669. doi: 10.2337/diacare.20.11.1664 |
[4]
|
Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China[J]. N Engl J Med, 2010, 362: 1090-1101. doi: 10.1056/NEJMoa0908292 |
[5]
|
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults[J]. JAMA, 2013, 310: 948-959. doi: 10.1001/jama.2013.168118 |
[6]
|
Wang L, Gao P, Zhang M, et al. Prevalence and Ethnic Pattern of Diabete and Prediabetes in China in 2013[J]. JAMA, 2017, 317: 2515-2523. doi: 10.1001/jama.2017.7596 |
[7]
|
国家统计局. 第七次全国人口普查公报(第五号)[EB/OL ]. (2021-05-11)[2022-04-11]. http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html. |
[8]
|
Yan ST, Li CX, Li CL, et al. Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics[J]. Genet Mol Res, 2015, 14: 3062-3070. |
[9]
|
Tinsley LJ, Kupelian V, D'Eon SA, et al. Association of Glycemic Control With Reduced Risk for Large-Vessel Disease After More Than 50 Years of Type 1 Diabetes[J]. J Clin Endocrinol Metab, 2017, 102: 3704-3711. doi: 10.1210/jc.2017-00589 |
[10]
|
Thompson TJ, Engelgau MM, Hegazy M, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults[J]. Diabet Med, 1996, 13: 337-340. doi: 10.1002/(SICI)1096-9136(199604)13:4<337::AID-DIA71>3.0.CO;2-A |
[11]
|
Hou JN, Bi YF, Xu M, et al. The change points of HbA(1C) for detection of retinopathy in Chinese type 2 diabetic patients[J]. Diabetes Res Clin Pract, 2011, 91: 401-405. doi: 10.1016/j.diabres.2010.11.029 |
[12]
|
Lindström J, Peltonen M, Eriksson JG, et al. Improved lifestyle and decreased diabetes risk over 13years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS)[J]. Diabetologia, 2013, 56: 284-293. doi: 10.1007/s00125-012-2752-5 |
[13]
|
Kawamori R, Tajima N, Iwamoto Y, et al. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance[J]. Lancet, 2009, 373: 1607-1614. doi: 10.1016/S0140-6736(09)60222-1 |
[14]
|
Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes[J]. N Engl J Med, 2008, 358: 580-591. doi: 10.1056/NEJMoa0706245 |
[15]
|
Gæde P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21years follow-up on the Steno-2 randomised trial[J]. Diabetologia, 2016, 59: 2298-2307. doi: 10.1007/s00125-016-4065-6 |
[16]
|
ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes[J]. N Engl J Med, 2008, 358: 2560-2572. doi: 10.1056/NEJMoa0802987 |
[17]
|
Gerstein HC, Riddle MC, Kendall DM, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial[J]. Am J Cardiol, 2007, 99: 34i-43i. |
[18]
|
van Hateren KJ, Landman GW, Kleefstra N, et al. Glycae-mic control and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20)[J]. Int J Clin Pract, 2011, 65: 415-419. doi: 10.1111/j.1742-1241.2010.02596.x |
[19]
|
American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetesd 2018[J]. Diabetes Care, 2018, 41: S55-S64. |
[20]
|
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on The Comprehensive Type 2 Diabetes Management ALGORITHM-2017 Executive Summary[J]. Endocr Pract, 2017, 23: 207-238. |
[21]
|
Araki E, Haneda M, Kasuga M et al. New glycemic targets for patients with diabetes from the Japan Diabetes Society[J]. J Diabetes Investig, 2017, 8: 123-125. doi: 10.1111/jdi.12600 |
[22]
|
Lu JY, Ma XJ, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes[J]. Diabetes Care, 2018, 41: 2370-2376. doi: 10.2337/dc18-1131 |
[23]
|
戴冬君, 陆静毅, 张磊, 等. 应用葡萄糖在目标范围内时间评价2型糖尿病血糖控制情况的适宜切点分析[J]. 中华医学杂志, 2020, 100: 2990-2996. doi: 10.3760/cma.j.cn112137-20200619-01895
Dai DJ, Lu JY, Zhang L, et al. The appropriate cut-off point of time in range (TIR) for evaluating glucose control in type 2 diabetes mellitus[J]. Zhognhua Yixue Zazhi, 2020, 100: 2990-2996. doi: 10.3760/cma.j.cn112137-20200619-01895 |
[24]
|
Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study[J]. Diabetes Care, 2021, 44: 549-555. doi: 10.2337/dc20-1862 |
[25]
|
Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range[J]. Diabetes Care, 2019, 42: 1593-1603. |
[26]
|
中国老年保健医学研究会老年内分泌与代谢病分会, 中国毒理学会临床毒理专业委员会. 老年人多重用药安全管理专家共识[J]. 中国全科医学, 2018, 21: 3533-3544. doi: 10.12114/j.issn.1007-9572.2018.00.225 |
[27]
|
Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years[J]. Clin Ther, 2012, 34: 2082-2090. |
[28]
|
Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOMEⓇ trial[J]. J Diabetes Investig, 2019, 10: 760-770. |
[29]
|
Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial[J]. Lancet Diabetes Endocrinol, 2019, 7: 606-617. |
[30]
|
Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study[J]. Diabetes Res Clin Pract, 2019, 151: 20-32. |
[31]
|
Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis[J]. Lancet, 2016, 387: 435-443. |
[32]
|
高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识[J]. 中华内科杂志, 2017, 56: 235-248. |
[33]
|
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志, 2020, 36: 1-13. https://www.cnki.com.cn/Article/CJFDTOTAL-LCLZ202007023.htm |
[34]
|
Ferrari SL, Abrahamsen B, Napoli N, et al. Diagnosis and management of bone fragility in diabetes: an emerging challenge[J]. Osteoporos Int, 2018, 29: 2585-2596. |
[35]
|
吴芸杨, 陈晓宏, 季晶俊, 等. 肌肉衰减综合征的诊断和治疗进展[J]. 医学综述, 2020, 26: 4499-4503. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZS202022025.htm
Wu YY, Chen XH, Ji JJ, et al. Research Progress of Diagnosis and Treatment of Sarcopenia[J]. Yixue Zongshu, 2020, 26: 4499-4503. https://www.cnki.com.cn/Article/CJFDTOTAL-YXZS202022025.htm |
[36]
|
Boccardi V, Murasecco I, Mecocci P. Diabetes drugs in the fight against Alzheimer's disease[J]. Ageing Res Rev, 2019, 54: 100936. |
[37]
|
Lee AA, Piette JD, Heisler M, et al. Diabetes self-management and glycemic control: The role of autonomy support from informal health supporters[J]. Health Psychol, 2019, 38: 122-132. |
[38]
|
Lee AA, Heisler M, Trivedi R, et al. Autonomy support from informal health supporters: links with self-care activi-ties, healthcare engagement, metabolic outcomes, and cardiac risk among Veterans with type 2 diabetes[J]. J Behav Med, 2021, 44: 241-252. |
[39]
|
Koetsenruijter J, Eikelenboom Nv, Lieshout Jv, et al. Social support and self-management capabilities in diabetes patients: An international observational study[J]. Patient Educ Couns, 2016, 99: 638-643. |